Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials.

Christensen, E., Evans, K.R., Menard, C., Pintilie, M., Bristow, R.G.
Journal   Cancer Metastasis Rev.
Analytes Measured  
Matrix Tested  
Year   2008
Volume   27
Page Numbers   375-85
INTRODUCTION: Proteomic biomarkers may be useful for monitoring therapeutic response and to triage cancer patients to best therapy. OBJECTIVES: In this review, we highlight the importance of specimen acquisition, preparation and analysis in radiotherapy proteomic studies. We also discuss practical approaches for the design and execution of clinical proteomic studies using our recent experience based on specimens accrued during prostate cancer radiation therapy. DISCUSSION AND

CONCLUSIONS: Numerous proteomic methods are being employed, including high-throughput mass spectrometry and immunoassays, and using solid tissues, blood and urine for analysis. Given the potential complexity of cytokine and other protein responses, there is a need to assess proteomic signatures within serial samples as longitudinal studies during a course of fractionated radiotherapy (RT).

View Publications
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters